Zacks Research Issues Positive Outlook for TSE:BHC Earnings

Bausch Health Companies Inc. (TSE:BHC) – Equities research analysts at Zacks Research boosted their FY2026 earnings per share (EPS) estimates for shares of Bausch Health Companies in a research note issued to investors on Tuesday, May 19th. Zacks Research analyst Team now anticipates that the company will post earnings of $5.38 per share for the year, up from their previous forecast of $5.32. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2027 earnings at $1.43 EPS.

Bausch Health Companies Stock Up 3.1%

Shares of Bausch Health Companies stock opened at C$7.56 on Thursday. The business’s fifty day moving average price is C$7.46 and its two-hundred day moving average price is C$8.46. The company has a debt-to-equity ratio of -1,009.96, a current ratio of 1.32 and a quick ratio of 0.58. The company has a market capitalization of C$2.82 billion, a P/E ratio of -2.33, a PEG ratio of 0.21 and a beta of 0.63. Bausch Health Companies has a 1-year low of C$6.06 and a 1-year high of C$11.97.

Bausch Health Companies (TSE:BHC) last announced its earnings results on Wednesday, April 29th. The company reported C$1.08 earnings per share for the quarter. The firm had revenue of C$3.51 billion for the quarter. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%.

Key Headlines Impacting Bausch Health Companies

Here are the key news stories impacting Bausch Health Companies this week:

• Positive Sentiment: Zacks Research raised its Q2 2026 EPS estimate to $1.31 from $1.28, and lifted Q4 2026 EPS to $1.58 from $1.49, which suggests improved near-term profitability expectations for Bausch Health Companies Inc. (TSE:BHC).
• Positive Sentiment: The company announced results from its 2026 annual meeting of shareholders, a sign of ongoing corporate governance activity with no negative surprise attached. Bausch Health Announces 2026 Annual Meeting of Shareholder Results
• Neutral Sentiment: Analyst forecasts were updated across several future periods, with some slight increases and some slight decreases, leaving the longer-term outlook mixed overall for Bausch Health Companies Inc. (TSE:BHC).
• Negative Sentiment: Zacks Research cut its estimates for Q3 2026, Q4 2027, FY2027, and FY2028, signaling some caution about earnings growth beyond the near term for Bausch Health Companies Inc. (TSE:BHC).

Bausch Health Companies Company Profile

Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries.